Mpex Pharmaceuticals Presents Positive Phase 2 Clinical Trial Results Of Aeroquin(TM) (MP-376) Treatment In Cystic Fibrosis Patients
Originally posted in Cystic Fibrosis News From Medical News Today
Mpex Pharmaceuticals, Inc. announced the presentation of data from its Phase 2b clinical trial with Aeroquin™ (a proprietary aerosol formulation of levofloxacin, MP-376) in cystic fibrosis (CF) at the American Thoracic Society (ATS) Annual Meeting in New Orleans…
No Comments
RSS feed for comments on this post.
by Raelene
